SEC Comment Letter 0000000000-23-013820 to Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733) (AQST)
Aquestive Therapeutics, Inc. (AQST) (CIK 0001398733)
Date: Dec. 19, 2023 · CIK: 0001398733 · Accession: 0000000000-23-013820
AI Filing Summary & Sentiment
File numbers found in text: 001-38599
Letter
United States securities and exchange commission logo December 19, 2023 A. Ernest Toth, Jr. Chief Financial Officer Aquestive Therapeutics, Inc. 30 Technology Drive Warren, NJ 07059 Re:Aquestive Therapeutics, Inc. Form 10-K for the fiscal year ended December 31, 2022 Filed March 31, 2023 File No. 001-38599 Dear A. Ernest Toth, Jr. : We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
December 19, 2023
A. Ernest Toth, Jr.
Chief Financial Officer
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, NJ 07059
Re:Aquestive Therapeutics, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Filed March 31, 2023
File No. 001-38599
Dear A. Ernest Toth, Jr. :
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences